US4192891A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Prostacyclin analogs and their use in inhibition of arachidonic acid-induced platelet aggregation and bronchoconstriction
Assignee: ER Squibb and Sons LLC
•
Filing: 1979-04-25
•
Granted: 1980-03-11
•
Expires: 1999-04-25
Abstract
Abstract Prostacyclin analogs are provided having the structure ##STR1## wherein X represents ═O or OH, R 1 and R 2 are OH or H, provided at least one of R 1 and R 2 is other than hydroxyl, R 3 is H or alkyl of 1 to 4 carbons, m is an integer of from 2 to 5, and n is an integer of from 2 to 10, or pharmaceutically acceptable salts thereof. These compounds have been found to be potent inhibitors of arachidonic acid-induced platelet aggregation and bronchoconstriction.
Inventors
- 👤 Martin F. Haslanger
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 08:36
CPC Classifications
C; C07; C07D; C07D309/00; C07D309/02; C07D309/08; C07D309/10; C07D309/12; A; A61; A61P; A61P11/00; A61P11/08; A61P7/00; A61P7/02; C07C; C07C405/00; C07C405/005; C07C405/0075; C07C405/0083
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
74 words
A compound of the structure ##STR27## wherein X represents ═O or --OH, R 1 and R 2 are OH or H, provided at least one of R 1 and R 2 is other than hydroxyl, R 3 is hydrogen or lower alkyl containing 1 to 4 carbons, m is an integer of from 2 to 5, and n is an integer of from 2 to 10, and pharmaceutically acceptable salts thereof, and isomers thereof.
Claim 2
Dependent Claim
74 words
A compound of the structure ##STR27## wherein X represents ═O or --OH, R 1 and R 2 are OH or H, provided at least one of R 1 and R 2 is other than hydroxyl, R 3 is hydrogen or lower alkyl containing 1 to 4 carbons, m is an integer of from 2 to 5, and n is an integer of from 2 to 10, and pharmaceutically acceptable salts thereof, and isomers thereof.
Claim 3
Dependent Claim
11 words
The compound as defined in claim 1 wherein X is ═O.
Claim 4
Dependent Claim
11 words
The compound as defined in claim 1 wherein X is --OH.
Claim 5
Dependent Claim
15 words
The compound as defined in claim 1 wherein m is 3 and n is 5.
Claim 6
Dependent Claim
17 words
The compound as defined in claim 1 wherein R 1 is OH and R 2 is H.
Claim 7
Dependent Claim
16 words
The compound as defined in claim 1 wherein R 1 and R 2 are each hydrogen.
Claim 8
Dependent Claim
12 words
The compound as defined in claim 1 wherein R 3 is alkyl.
Claim 9
Dependent Claim
12 words
The compound as defined in claim 1 wherein R 3 is H.
Claim 10
Dependent Claim
16 words
The compound as defined in claim 1 wherein R 3 is alkyl, and X is ═O.
Claim 11
Dependent Claim
16 words
The compound as defined in claim 1 wherein R 3 is alkyl, and X is OH.
Claim 12
Dependent Claim
16 words
The compound as defined in claim 1 wheren R 3 is H, and X is ═O.
Claim 13
Dependent Claim
16 words
The compound as defined in claim 1 wherein R 3 is H, and X is OH.
Claim 14
Dependent Claim
11 words
The compound a defined in claim 1 having the structure ##STR28##
Claim 15
Dependent Claim
11 words
The compound as defined in claim 13 having the structure ##STR29##
Claim 16
Dependent Claim
11 words
The compound as defined in claim 13 having the structure ##STR30##
Claim 17
Dependent Claim
11 words
The compound as defined in claim 13 having the structure ##STR31##
Claim 18
Dependent Claim
11 words
The compound as defined in claim 1 having the structure ##STR32##
Claim 19
Dependent Claim
38 words
A method of inhibiting arachidonic acid-induced platelet aggregation and bronchoconstriction, which comprises administering to the circulatory system of a mammalian host an effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof.
Claim 20
Dependent Claim
26 words
The method as defined in claim 18 wherein said compound is administered in an amount within the range of from about 1 to about 100 mg/kg.
Claim 21
Dependent Claim
30 words
A composition for inhibiting arachidonic acid-induced platelet aggregation and bronchoconstriction, comprising a compound as defined i claim 1 or a pharmaceutically acceptable salt thereof, and a parmaceutically acceptable carrier therefor.
Claim 22
Dependent Claim
30 words
A method of inhibiting platelet aggregation which comprises administering to a mammalian host an effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof.
Claim 23
Dependent Claim
32 words
A method of inhibiting bronchoconstriction associated with asthma, which comprises administering to a mammalian host an effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1983-03-11 | 1983-09-10 | 1984-03-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1987-03-11 | 1987-09-10 | 1988-03-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1991-03-11 | 1991-09-10 | 1992-03-11 | $7700.00 | Window Closed / Lapsed |